InflaRx NV (IFRX)
NASDAQ NMS - GLOBAL MARKET · Biotechnology
€1.69-0.01 (-0.59%)Quote refreshed
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Market Cap
$248.9M
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
—
Beta
—
Company overview
No company overview is available for InflaRx NV yet.
Peers in Biotechnology
All in industry →VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%
Recent press releases
InflaRx NV has not issued a press release in this window.
SEC filings
All filings →InflaRx NV has not filed an SEC document in this window.
Insider trades
All insider trades →InflaRx NV has no reported insider trades in the last 90 days.
Institutional holders
All holders →As of 2025-12-31 · prior 2025-09-30
2,475,000 sh0.0%
7,933,910 sh+22.4%
1,757,312 sh+1.5%
TWO SIGMA INVESTMENTS, LP$410,378
406,315 sh● NEW
3,315,000 sh+47.3%
T3 Companies, LLC$293,924
291,014 sh● NEW
MORGAN STANLEY$1.1M
1,061,234 sh+69.4%
RAYMOND JAMES FINANCIAL INC$395,937
392,017 sh-14.4%
People at InflaRx NV
All people →Quarterly financials
Full financials →Revenue trend
12/24
—
NI —
RevenueNI = Net Income
EPS trend (diluted)
EPS history not available.